Therapeutic antibodies, vaccines and antibodyomes

被引:97
作者
Dimitrov, Dimiter S. [1 ]
机构
[1] NCI, Prot Interact Grp, Ctr Canc Res, Nanobiol Program,NIH, Frederick, MD 21701 USA
关键词
antibodies; therapeutics; vaccines; antibodyome; biologicals; HUMAN MONOCLONAL-ANTIBODIES; HIV-1 NEUTRALIZING ANTIBODIES; PROTEIN THERAPEUTICS; INFLUENZA VACCINES; BREAST-CANCER; IMMUNOGENICITY; THERAPIES; IDENTIFICATION; VIRUSES; LIBRARY;
D O I
10.4161/mabs.2.3.11779
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The potential for antibodies to act as "magic bullets" for treatment of human disease was recognized a century ago, but its full realization has began to occur only during the last decade. A key to their current success is the ability to make libraries of antibodies/B cells, isolate a single species, and engineer it to be safe, efficacious and of high quality. Despite this progress, major challenges to the effective prevention, diagnosis and treatment of a vast majority of diseases remain. Limited success in the development of effective vaccines against diseases such as AIDS and cancer reflects our incomplete understanding of how antibodies are generated and function. Only a miniscule number of antibodies are characterized out of the universe of antibodies generated by the immune system. Knowledge of antibodyomes the complete sets of antibodies could help solve these and other challenges.
引用
收藏
页码:347 / 356
页数:10
相关论文
共 71 条
  • [1] Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
    Ashkenazi, Avi
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) : 1001 - 1012
  • [2] Baker MP, 2007, CURR OPIN DRUG DISC, V10, P219
  • [3] Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy
    Baxevanis, Constantin N.
    Perez, Sonia A.
    Papamichail, Michael
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (03) : 317 - 324
  • [4] Current Paradigms for the Use of HER2-Targeted Therapy in Early-Stage Breast Cancer
    Bedard, Philippe L.
    Piccart-Gebhart, Martine J.
    [J]. CLINICAL BREAST CANCER, 2008, 8 : S157 - S165
  • [5] TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
    Bellail, Anita C.
    Qi, Ling
    Mulligan, Patrick
    Chhabra, Vaninder
    Hao, Chunhai
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (01) : 34 - 41
  • [6] Antibody production
    Birch, John R.
    Racher, Andrew J.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) : 671 - 685
  • [7] Therapeutic Potential of Vaccines in the Management of Hypertension
    Brown, Morris J.
    [J]. DRUGS, 2008, 68 (18) : 2557 - 2560
  • [8] Antibodies, viruses and vaccines
    Burton, DR
    [J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (09) : 706 - 713
  • [9] A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
    Cameron, David
    Casey, Michelle
    Press, Michael
    Lindquist, Deborah
    Pienkowski, Tadeusz
    Romieu, C. Gilles
    Chan, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Kaufman, Bella
    Crown, John
    Chan, Arlene
    Campone, Mario
    Viens, Patrice
    Davidson, Neville
    Gorbounova, Vera
    Raats, Johannes Isaac
    Skarlos, Dimosthenis
    Newstat, Beth
    Roychowdhury, Debasish
    Paoletti, Paolo
    Oliva, Cristina
    Rubin, Stephen
    Stein, Steven
    Geyer, Charles E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) : 533 - 543
  • [10] Newer monoclonal antibodies for hematological malignancies
    Castillo, Jorge
    Winer, Eric
    Quesenberry, Peter
    [J]. EXPERIMENTAL HEMATOLOGY, 2008, 36 (07) : 755 - 768